Caris Life Sciences shared finalized Achieve I results for its multi-cancer early detection test Caris Detect, driving a sharp stock reaction. The study enrolled 3,014 evaluable patients and reported sensitivity ranging from 56.8% for stage I to 79% for stage III, with stage IV sensitivity of 98.6%. Specificity was reported as 99.2% for asymptomatic samples and 96% for benign/high-risk groups. Caris Detect uses whole-genome sequencing with Caris molecular profiling to generate marker data for AI models, aiming to identify early-stage molecular signals across diverse cancer types. Caris said it expects to launch Caris Detect in Q2 2026, with plans to incorporate additional modalities such as whole-transcriptome sequencing to strengthen performance. The finalized dataset moves the company from interim reporting toward a more complete performance assessment, an inflection point for early detection tests seeking broader clinical and commercial adoption.